Nathan den Broeder

Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients

Michiel E. de Jong, Lisa Smits, B van Ruijven et al. · Journal of Crohn s and Colitis · 2020 · 71 citations · Full text

Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial

Diane Marsman, Nathan den Broeder, F.H.J. van den Hoogen et al. · The Lancet Rheumatology · 2021 · 49 citations

Rheumatoid Disorder, Rheumatology, Proof-of-concept Trial +11

Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis

Lieke Tweehuysen, Nathan den Broeder, Noortje van Herwaarden et al. · RMD Open · 2018 · 39 citations · Full text

Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial

Celia A J Michielsens, Nathan den Broeder, F.H.J. van den Hoogen et al. · Annals of the Rheumatic Diseases · 2022 · 33 citations · Full text

Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial

Lise M Verhoef, Nathan den Broeder, Rogier M. Thurlings et al. · The Lancet Rheumatology · 2019 · 32 citations

Rheumatoid Disorder, Rheumatology, Allergy +9